GlassScriptPhysician profile
Soo Jin Lee
NPI 1457702862
$7,006.03
in general payments reported to CMS, 2019-2025
40 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $1,449 · 2021: $884 · 2022: $831 · 2023: $554 · 2024: $821 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $792.45 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $621.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $571.96 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $524.08 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.95 | 2019-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $369.82 | 2019-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $347.66 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Sumitomo Pharma America, INC. | $321.36 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $308.71 | 2020-2024 | |
| Amarin Pharma, INC. | $286.52 | 2020-2022 | |
| Abbvie INC. | $257.00 | 2021-2025 | |
| Lilly USA, LLC | $232.81 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $229.35 | 2019-2025 | |
| Daiichi Sankyo INC. | $216.05 | 2019-2022 | |
| Astellas Pharma US INC | $210.45 | 2024-2025 | Veozah |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $165.66 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $158.59 | 2019-2022 | |
| Stryker Corporation | $140.95 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $108.11 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $101.96 | 2020-2025 | Austedo Xr |
| Esperion Therapeutics, INC. | $89.44 | 2020-2025 | Nexletol |
| Corcept Therapeutics | $60.40 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $54.83 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.73 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $34.14 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $26.87 | 2020 | |
| Neurocrine Biosciences, INC. | $25.95 | 2025 | |
| Genentech USA, INC. | $24.68 | 2019 | |
| Biotronik Nro, INC. | $23.57 | 2025 | Prospera |
| Lundbeck LLC | $19.71 | 2025 | Rexulti |
| Shield Therapeutics INC | $18.50 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $17.08 | 2025 | Uptravi, Opsumit |
| Kyowa Kirin, INC. | $16.77 | 2024 | Crysvita |
| Boston Scientific Corporation | $15.17 | 2025 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2023 | Xifaxan, Trulance |
| C2n Diagnostics, LLC | $14.14 | 2025 | Precivityad2 |
| Tonix Medicines, INC. | $14.05 | 2025 | Tonmya |
| Eisai INC. | $13.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.76 | 2022 | |
| Clarus Therapeutics INC. | $9.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soo Jin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.